Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last kr12.60 DKK
Change Today -0.20 / -1.56%
Volume 82.1K
EXQ On Other Exchanges
As of 11:00 AM 05/27/15 All times are local (Market data is delayed by at least 15 minutes).

exiqon a/s (EXQ) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/7/15 - kr12.80
52 Week Low
10/3/14 - kr4.40
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for EXIQON A/S (EXQ)

Related News

No related news articles were found.

exiqon a/s (EXQ) Related Businessweek News

No Related Businessweek News Found

exiqon a/s (EXQ) Details

Exiqon A/S provides life science research products worldwide. It operates through two segments, Life Sciences and Diagnostics. The company’s products serve as a platform for the development of molecular diagnostic tests. It develops molecular diagnostic tests in collaboration with pharmaceutical and diagnostic companies. The company’s products include miRCURY RNA isolation kits; microRNA Array system, a system for global microRNA expression profiling; microRNA qPCR system, which enables microRNA expression profiling; microRNA detection probes that are used for the ultra-sensitive, and detection of microRNAs by Northern blot analysis and in situ hybridization; and microRNA inhibitor and target site blockers for functional analysis. It also offers microarrays capture probes for expression analysis of splice variants, small RNAs, and mRNA; qPCR assays for mRNA and ncRNA; RNA detection probes for in situ hybridization and Northern blot; and longRNA GapmeR, which are antisense oligonucleotides used for the inhibition of mRNA and lncRNA function. In addition, the company provides oligonucleotides and microarray capture probes to detect single nucleotide polymorphism; FISH probes to detect chromosomal DNA sequences; custom LNA oligonucleotides; LNA phosphoramidites for the synthesis of LNA containing oligonucleotides; and A2-quencher phosphoramidite, a dark quencher for real-time PCR probes. Further, it offers RNA isolation services for the sample types, including exosome isolation, blood derived serum, plasma and other bio-fluids, clinical FFPE and fresh frozen tissues, and cell lines; MicroRNA array and profiling services; microRNA and Small RNA sequencing services; microRNA in situ hybridization screening services; and custom pharma services, such as biomarker discovery, validation experiments, and others. The company markets its research products through direct sales, distributors, and the Web. Exiqon A/S was founded in 1995 and is headquartered in Vedbæk, Denmark.

91 Employees
Last Reported Date: 05/7/15
Founded in 1995

exiqon a/s (EXQ) Top Compensated Officers

Chief Executive Officer, President and Member...
Total Annual Compensation: kr3.3M
Chief Financial Officer and Member of Executi...
Total Annual Compensation: kr2.2M
Compensation as of Fiscal Year 2014.

exiqon a/s (EXQ) Key Developments

Exiqon A/S Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Reiterates Earnings Guidance for 2015

Exiqon A/S reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported revenue of DKK 39,022,000 against DKK 32,471,000 a year ago. Operating profit was DKK DKK 949,000 against operating loss of DKK 471,000 a year ago. Profit for the period was DKK 23,000 or DKK 0.00 per diluted share against DKK 793,000 or DKK 0.02 per diluted share a year ago. Cash flows from operating activities were DKK 1,213,000 against cash flows used in operating activities of DKK 2,312,000 a year ago. Acquisition of property, plant and equipment was DKK 246,000 against DKK 480,000 a year ago. Loss before tax was DKK 76 million against DKK 248 million a year ago. EBITDA was DKK 2.7 million against DKK 1.6 million a year ago. Acquisition of intangible assets was DKK 333,000 against DKK 502,000 a year ago. The company reiterates its full year guidance of revenues between DKK 150-160 million and EBITDA of DKK 5-10 million based on an average USD/DKK exchange rate of DKK 6.50.

Exiqon A/S Approves Appointment of Rodney Turner as New Member

The annual general meeting of Exiqon A/S was held on 19 March 2015, the shareholders approved the appointment of Rodney Turner as a new member of the company’s supervisory board.

Transgenomic, Inc. Expands License Agreement with Exiqon A/S to Support Global Commercialization of its Multiplexed ICE COLD-PCRTM for Cancer Liquid Biopsies

Transgenomic Inc. announced that it has signed an amended license agreement with Exiqon A/S for the expansion of rights to their proprietary Locked Nucleic Acid (LNA) oligonucleotides, which offer dramatically improved sensitivity and specificity compared to traditional DNA chemistries. The amended agreement provides Transgenomic with access to LNA oligos for use with all of the company’s proprietary ultra-high sensitivity mutation enrichment technologies, including its Multiplexed ICE COLD-PCRTM (MX-ICP). It covers Transgenomic’s commercial worldwide use of LNA oligos for analysis of all cancer genes on all platforms, including cutting edge approaches such as next-generation sequencing. This expanded agreement supports the global commercialization of revolutionary Multiplexed ICE COLD-PCR enrichment technology. Use of Exiqon’s LNA oligos with MX-ICP technology significantly enhances identification of very low concentration cancer mutations in liquid biopsies. This is vital to enabling clinicians to initially choose the right mutation-targeted cancer therapy and also enables them to monitor the cancer and detect emerging resistance to drugs over the course of treatment. Use of LNAs enables MX-ICP to work equally well in all tumor DNA analyses, whether in tissue biopsies or in blood- or urine-based liquid biopsies. Transgenomic’s Multiplexed ICE COLD-PCR offers major advantages for users of current sequencing technologies. It delivers at least a 100-fold improvement in sensitivity compared to standard methodologies and enriches both known and previously unknown genetic alterations in any gene using a single multiplexed assay. The ultra-high sensitivity of MX-ICP makes it feasible to conduct comprehensive genomic analyses using either tissue or liquid biopsies. MX-ICP is both platform agnostic and compatible with all sequencing platforms found in labs today, including the newest ultra-high throughput NGS instruments. MX-ICP is robust, easy to use and easily implemented, requiring minimal disruption to established sequencing workflows.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EXQ:DC kr12.60 DKK -0.20

EXQ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Fluidigm Corp $24.74 USD +0.43
HTG Molecular Diagnostics Inc $14.28 USD +0.45
Luminex Corp $16.71 USD +0.32
NanoString Technologies Inc $13.58 USD -0.42
WaferGen Bio-systems Inc $3.53 USD -0.14
View Industry Companies

Industry Analysis


Industry Average

Valuation EXQ Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.5x
Price/Book 6.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EXIQON A/S, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at